Loading…
Budgeting for Opioid Addiction Treatment Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Budgeting for Opioid Addiction Treatment Act This bill amends the Internal Revenue Code to impose a one cent per milligram excise tax on the sale of active opioids by the manufacturer, producer, or importer. The tax excludes prescription drugs used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort. The Department of Health and Human Services (HHS) must establish a program to provide rebates or discounts to cancer and hospice patients to ensure that they do not pay the tax. The bill amends the Public Health Service Act to require any increase in federal revenues from the tax after rebates and discounts are subtracted to be distributed to states under the Substance Abuse Prevention and Treatment Block Grant program to be used exclusively for substance abuse (including opioid abuse) efforts in the states, including specified treatment programs. HHS must report to Congress on the impact of this bill on the retail cost of opioids and patient access to opioid medication, the effectiveness of the discount or rebate for cancer and hospice patients, how the funds are being used to improve substance abuse treatment efforts, and suggestions for improving access to opioids for cancer and hospice patients and substance abuse treatment efforts.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2016 · third_quarter · Taxation/Internal Revenue Code
Taxation Issues Related to Opioid Pharmaceuticals. S.3075: Addiction Prevention and Responsible Opioid Practices Act. S.2977: Budgeting for Opioid Addiction Treatment Act.
Client expense: $570,000 · Firm income: Not reported
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Taxation/Internal Revenue Code
Taxation Issues Related to Opioid Pharmaceuticals. S.3075: Addiction Prevention and Responsible Opioid Practices Act. S.2977: Budgeting for Opioid Addiction Treatment Act.
Client expense: $800,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2016 · third_quarter · Taxation/Internal Revenue Code
Taxation Issues Related to Opioid Pharmaceuticals. S.3075: Addiction Prevention and Responsible Opioid Practices Act. S.2977: Budgeting for Opioid Addiction Treatment Act.
Client expense: $569,598 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Pharmacy
Policy matters related to generic pharmaceuticals and biosimilars including naming, labeling, access and interchangeability and changes to the Risk Evaluation and Mitigation Strategies (REMS) program, H.R.2841, FAST Generics Act of 2015 and S.3056, The CREATES Act, access to samples for generic testing, including S.3455, the Pharmaceutical Supply and Value Enhancement (SAVE) Act. The 21st Century Cures Act included in H. R. 2028, Further Continuing and Security Assistance Appropriations Act for Fiscal Year 2017. Affordability and pricing of pharmaceuticals. Issues related to drug takeback and opioid addiction. H. R. 4931, The Pharmaceutical Stewardship Act of 2016 and S.2977, The Budgeting for Opioid Addiction Treatment Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2016 · third_quarter · Taxation/Internal Revenue Code
Taxation Issues Related to Opioid Pharmaceuticals. S.3075: Addiction Prevention and Responsible Opioid Practices Act. S.2977: Budgeting for Opioid Addiction Treatment Act.
Client expense: $569,598 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Pharmacy
Policy matters related to generic pharmaceuticals and biosimilars including naming, labeling, access and interchangeability and changes to the Risk Evaluation and Mitigation Strategies (REMS) program, H.R.2841, FAST Generics Act of 2015 and S.3056, The CREATES Act, access to samples for generic testing, including S.3455, the Pharmaceutical Supply and Value Enhancement (SAVE) Act. H. R. 6, 21st Century Cures Act and the Senate Health, Education, Labor and Pensions Committee Initiative for Healthier Americans. Affordability and pricing of pharmaceuticals. Issues related to drug takeback and opioid addiction, including S.524 and H.R. 953, The Comprehensive Addiction and Recovery Act of 2016. H. R. 4931, The Pharmaceutical Stewardship Act of 2016 and S.2977, The Budgeting for Opioid Addiction Treatment Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2016 · second_quarter · Pharmacy
Policy matters related to generic pharmaceuticals and biosimilars including naming, labeling, access and interchangeability and changes to the Risk Evaluation and Mitigation Strategies (REMS) program, H.R.2841, FAST Generics Act of 2015 and S.3075, The CREATES Act, access to samples for generic testing. Issues related to House Energy and Commerce Committee's draft on H. R. 6, 21st Century Cures Act and the Senate Health, Education, Labor and Pensions Committee Initiative for Healthier Americans. Affordability and pricing of pharmaceuticals. Issues related to drug takeback and opioid addiction, including S.524 and H.R. 953, The Comprehensive Addiction and Recovery Act of 2016. H. R. 4931, The Pharmaceutical Stewardship Act of 2016 and S.2977, The Budgeting for Opioid Addiction Treatment Act.
Client expense: Not reported · Firm income: $60,000
2016 · second_quarter · Taxation/Internal Revenue Code
Taxation Issues Related to Opioid Pharmaceuticals. S.3075: Addiction Prevention and Responsible Opioid Practices Act. S.2977: Budgeting for Opioid Addiction Treatment Act.
Client expense: $802,333 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2015 · first_quarter · Health Issues
HR 3303 "SOFTWARE Act," all provisions pertaining to a framework for oversight of patient safety in health information technology. S 2977 "MEDTECH Act," all provisions pertaining to a framework for oversight of patient safety in health information technology. HR 2 "Medicare Access and CHIP Reauthorization Act of 2015," all provisions. S 810 "SGR Repeal and Medicare Provider Payment Modernization Act of 2015," all provisions. Issues relating to opposition to the current trajectory of the Meaningful Use program.
Client expense: $210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| FL |
| Brian Schatz | Democratic | HI |
| Christopher Murphy | Democratic | CT |
| Elizabeth Warren | Democratic | MA |
| Heidi Heitkamp | Democratic | ND |
| Jeanne Shaheen | Democratic | NH |
| Martin Heinrich | Democratic | NM |
| Tammy Baldwin | Democratic | WI |
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office